Osteoporosis in 2017

Addressing the crisis in the treatment of osteoporosis

A large number of patients with osteoporosis are not receiving appropriate treatment, due in part to concerns regarding drug safety. Great progress has been made to address this crisis in therapy in 2017, including highlighting the patients' views, developing new therapies and treatment strategies and addressing these safety concerns.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Advances in osteoporosis in 2017.

References

  1. 1

    Kalluru, R. et al. Randomised trial assessing the impact of framing of fracture risk and osteoporosis treatment benefits in patients undergoing bone densitometry. BMJ Open 7, e013703 (2017).

    Article  Google Scholar 

  2. 2

    Bone, H. G. et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 5, 513–523 (2017).

    CAS  Article  Google Scholar 

  3. 3

    Saag, K. G. et al. Romosozumab or alendronate for fracture prevention in women with osteo-porosis. N. Engl. J. Med. 377, 1417–1427 (2017).

    CAS  Article  Google Scholar 

  4. 4

    Kendler, D. L. et al. Effects of teriparatide and risedronate on new fractures in postmenopausal women with severe osteoporosis (VERO): a multicenter, double-blind, double-dummy, randomized controlled trial. Lancet 10.1016/S0140-6736(17)32137-2 (2017).

  5. 5

    Khosla, S. et al. A crisis in the treatment of osteoporosis. J. Bone Miner. Res. 31, 1485–1487 (2016).

    Article  Google Scholar 

  6. 6

    Alami, S. et al. Barriers to effective postmenopausal osteoporosis treatment: a qualitative study of patients' and practitioners' views. PLoS ONE 11, e0158365 (2016).

    Article  Google Scholar 

  7. 7

    Cummings, S. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756–765 (2009).

    CAS  Article  Google Scholar 

  8. 8

    Miller, P. D. et al. Effects of abaloparatide versus placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316, 722–733 (2016).

    CAS  Article  Google Scholar 

  9. 9

    Cosman, F. et al. Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatement with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial. Mayo Clin. Proc. 92, 200–210 (2017).

    CAS  Article  Google Scholar 

  10. 10

    Cosman, F. et al. Romosozumab treatment in post menopausal women with osteoporosis. N. Engl. J. Med. 375, 1532–1543 (2016).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Christian Roux.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Roux, C., Briot, K. Addressing the crisis in the treatment of osteoporosis. Nat Rev Rheumatol 14, 67–68 (2018). https://doi.org/10.1038/nrrheum.2017.218

Download citation

Further reading

Search

Sign up for the Nature Briefing newsletter for a daily update on COVID-19 science.
Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing